Delving into the Latest Updates on Triptorelin acetate with Synapse

To investigate the pharmacokinetics of triprerelin acetate for injection and triprerelin acetate (Dufferin ®) for injection of reference preparation in patients with prostate cancer by single intramusculodynamic injection in fasting state, and to evaluate the bioequivalence of the two formulations in fasting state.

Start Date04 Dec 2024

Sponsor / Collaborator

The Affiliated Hospital of Qingdao University

[+8]

CTR20243425

/ RecruitingNot Applicable

注射用醋酸曲普瑞林人体生物等效性研究

[Translation] Study on the bioequivalence of triptorelin acetate for injection in healthy volunteers

研究空腹状态下单次肌肉注射受试制剂注射用醋酸曲普瑞林与参比制剂注射用醋酸曲普瑞林（达菲林®）在前列腺癌患者体内的药代动力学，评价空腹状态下两种制剂的生物等效性和安全性。

[Translation]

To study the pharmacokinetics of a single intramuscular injection of the test formulation triptorelin acetate for injection and the reference formulation triptorelin acetate for injection (Diphylline®) in patients with prostate cancer under fasting conditions and to evaluate the bioequivalence and safety of the two formulations under fasting conditions.

Start Date22 Oct 2024

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

CTR20240796

/ RecruitingPhase 3

一项多中心、开放、单臂 III 期临床试验：评估注射用醋酸曲普瑞林微球治疗儿童中枢性性早熟的有效性和安全性

[Translation] A multicenter, open-label, single-arm phase III clinical trial to evaluate the efficacy and safety of triptorelin acetate microspheres for injection in the treatment of central precocious puberty in children

评价注射用醋酸曲普瑞林微球治疗中枢性性早熟（CPP）受试者的临床疗效。

[Translation]

To evaluate the clinical efficacy of triptorelin acetate microspheres for injection in the treatment of subjects with central precocious puberty (CPP).

Start Date14 Jul 2024

Sponsor / Collaborator

Lizhu Group Lizhu Medicine Research Institute

[+1]

100 Clinical Results associated with Triptorelin acetate

Login to view more data

100 Translational Medicine associated with Triptorelin acetate

Login to view more data

100 Patents (Medical) associated with Triptorelin acetate

Login to view more data

68

Literatures (Medical) associated with Triptorelin acetate

01 Dec 2024·Journal of Assisted Reproduction and Genetics

Dual trigger versus human chorionic gonadotropin trigger for blastocyst quality and cumulative live birth

Article

Author: Liu, Yalong ; Chi, Hongbin ; Li, Rong ; Liu, Xintong ; Zeng, Lin ; Lian, Ying ; He, Zining ; Huang, Ning

PURPOSETo evaluate the difference in the number of euploid blastocysts and cumulative live birth rate (LBR) between dual and human chorionic gonadotropin (hCG) triggers in poor and normal ovarian responders undergoing preimplantation genetic testing (PGT) cycles.METHODSThis retrospective cohort study was enrolled from July 2018 to December 2021 and followed up until June 2024 at a single reproductive medical center. Overall, 1040 in vitro fertilization (IVF)-PGT and 784 frozen-thawed embryo transfer (FET) cycles were assessed. Dual (triptorelin acetate 0.2 mg and recombinant hCG [rhCG] 250 µg) or hCG (rhCG 250 µg) trigger was used for oocyte maturation in the gonadotropin-releasing hormone antagonist protocol and PGT cycles. We assessed the embryo outcomes and FET cumulative pregnancy outcomes.RESULTSThe number of oocytes retrieved (10.17 ± 5.22 vs 10.27 ± 5.14, P = 0.789), MII oocytes (8.24 ± 4.26 vs 8.28 ± 4.05, P = 0.888), blastocysts (2.16 ± 1.50 vs 2.12 ± 1.49, P = 0.729), euploid blastocysts (1.06 ± 1.14 vs 1.09 ± 1.23, P = 0.726), and the rate of cumulative LBR (24.9% vs 24.9%, P = 1.000) in the dual trigger group were comparable with those in the hCG group. The trigger method was not correlated with higher LBR based on logistic regression analysis (odds ratio[OR] = 1.040 [0.778-1.392], P = 0.790).CONCLUSIONFor poor and normal ovarian responders, the dual trigger, compared with the hCG trigger, did not improve the PGT embryo outcomes and FET cumulative pregnancy outcomes.

30 Jun 2024·Annals of Pediatric Endocrinology & Metabolism

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty

Article

Author: Nam, Hyo-Kyoung ; Gwag, Si-Hwa ; Park, Kyu Hyun ; Rhie, Young-Jun ; Kim, Yu Jin ; Lee, Kee-Hyoung ; Kang, Eungu ; Chung, Lindsey Yoojin

Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; <i>p</i>=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.

01 Apr 2024·Clinical Endocrinology

Peak serum luteinising hormone cut‐off during gonadotropin‐releasing hormone analogue test for diagnosing central precocious puberty was lower in girls with obesity as compared with girls with normal weight

Article

Author: Sakornyutthadej, Natee ; Poomthavorn, Preamrudee ; Wankanit, Somboon ; Mahachoklertwattana, Pat

AbstractObjectiveSerum luteinising hormone (LH) concentration has been reported to be lower in girls with overweight and obesity (OW/OB) as compared with girls with normal weight (NW). This study aimed to evaluate peak serum LH concentration during gonadotropin‐releasing hormone analogue (GnRHa) test in girls with OW/OB and NW who had central precocious puberty (CPP) and to determine peak serum LH cut‐off for diagnosing CPP in girls with OW/OB.Design, Patients and MeasurementsMedical records of 971 girls with premature breast development who underwent subcutaneous GnRHa (100 µg of triptorelin acetate) test were reviewed. All girls were classified as either CPP or premature thelarche. All of them were further classified into two groups according to their body mass index as NW and OW/OB groups for each Tanner stage.ResultsThere were 634 and 337 girls in NW and OW/OB groups, respectively. CPP was diagnosed in 600 girls (249 had Tanner stage II and 351 had Tanner stage III). There were no differences in peak serum LH concentrations between CPP girls with NW and OW/OB. Peak serum LH cut‐off of 5 IU/L (the current widely used cut‐off) had a sensitivity and a specificity of 75% and 90%, respectively in NW group. Peak serum LH cut‐off for CPP diagnosis was lower at 4 IU/L in the OW/OB group with greater sensitivity and specificity of 86% and 93%, respectively. The results were reproducible for each Tanner stage of breasts.ConclusionLower peak serum LH cut‐off to 4 IU/L for diagnosing CPP in girls with OW/OB should be considered to avoid underdiagnosis of the condition.

100 Deals associated with Triptorelin acetate

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Endometriosis	CN	Livzon Pharmaceutical Group, Inc.	26 Sep 2024
Puberty, Precocious	AU	Ferring Pharmaceuticals Pty Ltd.	04 Mar 2015
Prostatic Cancer	CN	Changchun Genescience Pharmaceuticals Co., Ltd.	15 Sep 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Puberty, Precocious	NDA/BLA	CN	Changchun Genescience Pharmaceuticals Co., Ltd.	18 Apr 2024
Endometriosis	NDA/BLA	CN	Shanghai Livzon Pharmaceutical Co. Ltd.	24 Aug 2023
Prostatic Cancer	Discovery	CN	Shanghai Livzon Pharmaceutical Co. Ltd.	06 Apr 2020
HIV Infections	Discovery	SE	ISR Immune System Regulation AB	19 Sep 2018
HIV Infections	Discovery	DE	ISR Immune System Regulation AB	19 Sep 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2023	Not Applicable	Puberty, Precocious	148	Subcutaneous Triptorelin Acetate	uzqtbpraty(dekzattdwd) = enkvfbrosb daimyywine (pfwlpccrhh )	-	21 Sep 2023
ESPE2018	Not Applicable	Puberty, Precocious	-	Leuprorelin Acetate	bbwkimlekr(htkcjzrjld) = qceechgkvg tmoecpywjr (nttpzuupwm ) View more	Positive	27 Sep 2018
				Triptorelin Acetate	bbwkimlekr(htkcjzrjld) = gpjvujeqgv tmoecpywjr (nttpzuupwm ) View more
ASCO2017	Phase 2	Breast Cancer Neoadjuvant	41	Letrozole 2.5mg daily	(tljkwlmcve) = jqksbtpoui bsvicztmkl (axcjytfgxc ) View more	Positive	30 May 2017
				Combined with triptorelin in premenopausal patients	(tljkwlmcve) = dorpsetwbt bsvicztmkl (axcjytfgxc ) View more
ASCO_GU2016	Not Applicable	Prostatic Cancer Neoadjuvant \| Adjuvant	670	Buserelin	vuzgjqsonu(nqidbyggjy) = yeildbrydg uopjihoaih (ihwucrkled )	-	10 Jan 2016
				Goserelin	vuzgjqsonu(nqidbyggjy) = yuikybhpfa uopjihoaih (ihwucrkled )
ESPE2014	Not Applicable	Puberty, Precocious	14	Triptorelin acetate	(ckvuofxvql) = ldttmbicgq mtpxwpbogq (awtltmobqb )	-	18 Sep 2014
ASCO2008	Not Applicable	Breast Cancer Neoadjuvant	-	GnRH agonist (triptorelin)	vlcaegbstr(ouqjktsneu) = matknptcfm mmsyfcpqsl (snfxyunbef )	-	20 May 2008
				No triptorelin (control)	vlcaegbstr(ouqjktsneu) = gznyaknfvu mmsyfcpqsl (snfxyunbef )